logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9073855 B1

PDFFull Text
Date of Patent:
Jul. 07, 2015

Filed:

Mar. 15, 2013

Bcl-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases

Applicant:

Abbvie Inc., North Chicago, IL (US);

Inventors:

George A. Doherty, Libertyville, IL (US);

Steven W. Elmore, Northbrook, IL (US);

Lisa Hasvold, Grayslake, IL (US);

Laura Hexamer, Grayslake, IL (US);

Robert A. Mantei, Franklin, WI (US);

Andrew J. Souers, Evanston, IL (US);

Gerard M. Sullivan, Lake Villa, IL (US);

Zhi-Fu Tao, Gurnee, IL (US);

Gary T. Wang, Libertyville, IL (US);

Le Wang, Vernon Hills, IL (US);

Xilu Wang, Grayslake, IL (US);

Michael D. Wendt, Vernon Hills, IL (US);

Todd M. Hansen, Grayslake, IL (US);

Assignee:

ABBVIE INC., North Chicago, IL (US);

Attorney:

Jones Day

Primary Examiner:

Shawquia Jackson

Int. Cl.
CPC ...
C07D 401/10 (2006.01); C07D 213/62 (2006.01); C07D 307/02 (2006.01); C07D 215/14 (2006.01); C07D 209/32 (2006.01); C07D 211/96 (2006.01); C07D 213/64 (2006.01); C07D 215/20 (2006.01); C07D 217/16 (2006.01); C07D 231/56 (2006.01); C07D 235/26 (2006.01); C07D 249/04 (2006.01); C07D 295/125 (2006.01); C07D 295/14 (2006.01); C07D 309/14 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 417/12 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 295/13 (2006.01); C07D 309/08 (2006.01); C07D 487/04 (2006.01); C07D 209/20 (2006.01); C07D 295/155 (2006.01); C07D 309/32 (2006.01);
U.S. Cl.
CPC ...
C07D 215/14 (2013.01); C07D 209/32 (2013.01); C07D 211/96 (2013.01); C07D 213/64 (2013.01); C07D 215/20 (2013.01); C07D 217/16 (2013.01); C07D 231/56 (2013.01); C07D 235/26 (2013.01); C07D 249/04 (2013.01); C07D 295/125 (2013.01); C07D 295/14 (2013.01); C07D 309/14 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 417/12 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 295/13 (2013.01); C07D 309/08 (2013.01); C07D 487/04 (2013.01); C07D 209/20 (2013.01); C07D 295/155 (2013.01); C07D 309/32 (2013.01);
Abstract

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

Find Patent Forward Citations

Loading…